BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Methotrexate: trial readouts and FDA decisions
1 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 2 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: XBiotech, Inc., medac GmbH, Merck Sharp & Dohme LLC. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2027-01-15 est. | P2 | XBiotech, Inc. XBIT | NCT06590090 Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment | Rheumatoid Arthritis | not yet recruiting | 108 |
Readouts, last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11 est. | P3 | medac GmbH | NCT06239311 Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis. | Moderate to Severe Atopic Dermatitis | recruiting | 277 |
| 2026-09-07 | P2 | Merck Sharp & Dohme LLC MRK | NCT07176390 A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014) | Arthritis, Rheumatoid | active not recruiting | 185 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.